In terms of targeting the proliferation controlled by ELF3 therapeutically, our data would suggest extreme caution as compensatory activation of other ETS family members, most notably ETV5, which is a known oncogene in PCa, could result in cancer progression rather than regression. The gene discussed is ETV5; the disease is posterior cortical atrophy.